May 2014May 2014

A bio-pharmaceutical company developing treatmentsA bio-pharmaceutical company developing treatments for hypertension, diabetes , diabetic nephropathy and for hypertension, diabetes , diabetic nephropathy and

metabolic syndrome.metabolic syndrome.

1

Forward-Looking StatementsForward-Looking Statements

This document contains forward-looking information pursuant to This document contains forward-looking information pursuant to applicable securities law. All information that addresses activities or applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are based on the estimates and statements. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans or they should not be regarded as a representation that any of the plans or objectives will be achieved. Actual results may differ materially from objectives will be achieved. Actual results may differ materially from those expressed or implied by the forward-looking information set forth those expressed or implied by the forward-looking information set forth in this document due to risks and uncertainties affecting the Company, in this document due to risks and uncertainties affecting the Company, including access to capital, the successful completion of clinical trials and including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. The forward-looking statements in this receipt of all regulatory approvals. The forward-looking statements in this document are based on a number of assumptions which may prove to be document are based on a number of assumptions which may prove to be incorrect, including assumptions concerning general business and incorrect, including assumptions concerning general business and economic conditions, positive clinical trials and the availability of economic conditions, positive clinical trials and the availability of financing. XORTX assumes no responsibility to update forward-looking financing. XORTX assumes no responsibility to update forward-looking statements in this document.statements in this document.

2

XORTX Company OverviewXORTX Company Overview

• XORTX is a bio-pharmaceutical company founded on patents and patent XORTX is a bio-pharmaceutical company founded on patents and patent applications that include US and worldwide rights for the development of uric acid applications that include US and worldwide rights for the development of uric acid lowering agents to treat hypertension, diabetic nephropathy, insulin resistance, lowering agents to treat hypertension, diabetic nephropathy, insulin resistance, metabolic syndrome and diabetes. metabolic syndrome and diabetes.

• XORTX’s technology has been validated by successful phase II pilot trials in XORTX’s technology has been validated by successful phase II pilot trials in adolescent hypertension and chronic kidney injury. These trails demonstrated that adolescent hypertension and chronic kidney injury. These trails demonstrated that when uric acid levels are decreased, clinically meaningful reduction in hypertension when uric acid levels are decreased, clinically meaningful reduction in hypertension and decrease in progression of chronic kidney injury occurs. and decrease in progression of chronic kidney injury occurs.

• African Queen Mines Ltd. (TSX-V: AQ) (the “Company”) is acquiring all of the issued African Queen Mines Ltd. (TSX-V: AQ) (the “Company”) is acquiring all of the issued and outstanding securities of XORTX (a private CBCA company with approximately and outstanding securities of XORTX (a private CBCA company with approximately 38 shareholders) in a reverse take-over, by way of a share exchange agreement. 38 shareholders) in a reverse take-over, by way of a share exchange agreement.

• XORTX will become a wholly-owned subsidiary of the Company, which will change XORTX will become a wholly-owned subsidiary of the Company, which will change its name to reflect its new business.its name to reflect its new business.

• In connection with or prior to the Closing, the Company will complete a brokered In connection with or prior to the Closing, the Company will complete a brokered private placement to raise a minimum CDN $3,000,000 and up to CDN $6,000,000 private placement to raise a minimum CDN $3,000,000 and up to CDN $6,000,000 plus a 20% over-allotment option.plus a 20% over-allotment option.

3

Chronically increased Serum Uric Acid is a Chronically increased Serum Uric Acid is a Multi-modal Multi-modal causecause of hypertension. of hypertension.

Uric Acid a Novel Mechanism of Action for HypertensionUric Acid a Novel Mechanism of Action for Hypertension

1) Uric acid- Decreases Endothelial Nitric Oxide Production1) Uric acid- Decreases Endothelial Nitric Oxide Production

2) Uric acid- Increases Renin-Angiotensin-Aldosterone Activation2) Uric acid- Increases Renin-Angiotensin-Aldosterone Activation

3) Uric acid- Increases circulating Insulin concentration3) Uric acid- Increases circulating Insulin concentration

4) Insulin in absence during Nitric Oxide 4) Insulin in absence during Nitric Oxide

5) Uric Acid induces 5) Uric Acid induces glomerular - kidney injury glomerular - kidney injury

VASOCONSTRICTION

Mazzali et al Hypertension 38:1101-1106, 2001; JASN 2005; 16:35553-3562

Nakagawa et al, Am J Physiol 2006; 290:F625-631

Mazzali et al, AJP Renal Physiol 282:F991, 2002

SALT SENSITIVEHYPERTENSION

Reaven GM, Lithell H, Landsberg L. N Engl J Med. 1996;334(6):374-381.

Conclusion: Uric acid can Conclusion: Uric acid can causecause Progressive, Worsening HypertensionProgressive, Worsening Hypertension

VASOCONSTRICTION

VASOCONSTRICTION

VASOCONSTRICTION

Serum Uric Acid Serum Uric Acid “Disease Axis”“Disease Axis”

HypertensionHypertension

Serum Uric Acid Causes Serum Uric Acid Causes ““Disease Axis”Disease Axis”

Salt Sensitive HypertensionSalt Sensitive HypertensionInsulin ResistanceInsulin Resistance

DiabetesDiabetes

ObesityObesity

Vascular InjuryVascular Injury Kidney InjuryKidney Injury

Kidney loss, Blindness, Kidney loss, Blindness, Ischemic limbsIschemic limbs

BLOCKSBLOCKS Weight GainWeight Gain

DECREASESDECREASES High Blood PressureHigh Blood Pressure

May DecreaseMay Decrease Diabetes /Met SynDiabetes /Met Syn Insulin ResistanceInsulin Resistance

DECREASESDECREASES Renal Injury /Diabetic Renal Injury /Diabetic NephropathyNephropathy

Lowering Serum Uric Acid . . . Lowering Serum Uric Acid . . .

5

Non-Clinical Evidence Clinical Evidence

The Product Vision: XORLOThe Product Vision: XORLO

6

A Superior Uric Acid A Superior Uric Acid Lowering Agent For Lowering Agent For Controlling Blood Controlling Blood Pressure Pressure

New formulation New formulation includes proprietary includes proprietary molecule-Oxypurinol molecule-Oxypurinol with additives to with additives to improve bio availability.improve bio availability.

New Mechanism of ActionNew Mechanism of Action: Best “first choice” : Best “first choice” for treatment of Early-Stage Hypertensionfor treatment of Early-Stage Hypertension

A Solution with Strong Clinical ValidationA Solution with Strong Clinical ValidationAnd Multiple Therapeutic IndicationsAnd Multiple Therapeutic Indications

1.1.New Onset HypertensionNew Onset Hypertension• 2 Successful Phase II Clinical Trials- Show Uric Acid is a Causative Factor.2 Successful Phase II Clinical Trials- Show Uric Acid is a Causative Factor.

• Fieg D, et al, JAMA, 300(8):924:2008Fieg D, et al, JAMA, 300(8):924:2008

• Soletsky B. and Fieg D., Uric Acid Reduction Rectifies Prehypertension in Obese Soletsky B. and Fieg D., Uric Acid Reduction Rectifies Prehypertension in Obese Adolescents, Hypertension 60:1148: 2012Adolescents, Hypertension 60:1148: 2012

2.2.Prevention of Diabetes/Insulin ResistancePrevention of Diabetes/Insulin Resistance

3.3.Prevention of Diabetic NephropathyPrevention of Diabetic Nephropathy• 2 Successful Phase II Clinical Trials- Show Uric Acid Drives Injury2 Successful Phase II Clinical Trials- Show Uric Acid Drives Injury

• Siu YP, et al., Am J Kidney Dis, 47;1;2006Siu YP, et al., Am J Kidney Dis, 47;1;2006• Goicoechea, M., et al., Clin J Am Soc Nephrol, 5:1388;2010Goicoechea, M., et al., Clin J Am Soc Nephrol, 5:1388;2010

7

XORLO is being developed for the indications of Hypertension XORLO is being developed for the indications of Hypertension and Diabetic Nephropathy.and Diabetic Nephropathy.

Strong Correlation Between High Blood Pressure Strong Correlation Between High Blood Pressure and Increased Serum Uric Acid in Adolescentsand Increased Serum Uric Acid in Adolescents

R= 0.80

Feig D and R Johnson Hypertension 2003; 42:247-252

Uric Acid (mg/dl)

Systolic BP

(mm Hg)

8

Drug Intervention

LifeStyle Change

Randomized Independent Phase II Trial Success in Randomized Independent Phase II Trial Success in Obese, Hypertensive AdolescentsObese, Hypertensive Adolescents

Randomized trial of 60 obese, pre-hypertensive adolescents, treated for 2 months with Allopurinol to determine effect on blood pressure

Soletsky B. and Fieg D., Uric Acid Reduction Prehypertension in Obese Adolescents, Hypertension 60:1148: 2012

Oxypurinol is a metabolic Oxypurinol is a metabolic derivative of Allopurinolderivative of Allopurinol..

At 2 Months Allopurinol At 2 Months Allopurinol significantly decreased:significantly decreased:

Uric Acid: Uric Acid: -2.4 mg/dL (p=0.0005)

SBP: SBP: -11.8 mmHg (p=0.0001)DBP: DBP: - 9.6 mmHg (p=0.0002)

> 80% of individuals whose uric acid was lowered blood pressure was also normalized.

Weight:Weight: -3.1 kg (p=0.039)(N.B. Placebo Corrected Differences Reported)

9

$6.0 M

XORTX Program Milestones XORTX Program Milestones (66 Months to NDA)(66 Months to NDA)

20142014 20152015 20162016

XORLO XORLO – Early Stage / Type I Hypertension:– Early Stage / Type I Hypertension:

($15.2 M)

Phase II Phase II Phase III Phase III Phase III (if necessary) Phase III (if necessary)

XORLO XORLO –Treatment of Diabetic Nephropathy–Treatment of Diabetic Nephropathy

XORTX Operations:XORTX Operations:

($1.2 M/yr) ($1.2 M/yr) ($1.8 M/yr)

20172017 20182018

($1.8 M/yr) ($1.8 M/yr)

NDA

XORLO XORLO – Treatment of Diabetes/IR/ Met Syn – Treatment of Diabetes/IR/ Met Syn

($31 M)($3.6 M)

20192019

($1.8 M/yr)

($ XX,XXX,XXX)

FDA mtg.

PhII Approval

20202020

$18 M

($1.8 M/yr)

Pivotal Phase IIIPivotal Phase III

Pivotal Phase III Pivotal Phase III

License / Sell / Series C

Patent PortfolioPatent PortfolioComprised of 5 FamiliesComprised of 5 Families

URIC ACID LOWERING AGENTS (UALA)URIC ACID LOWERING AGENTS (UALA)

1- 1- Hypertension: Hypertension: US 7,799,794- Claim Granted “Allopurinol for the treatment of hypertension CIP: “All UALA for Hypertension” Exp-July 2022

2- 2- Treatment of Diabetes / Insulin Resistance:Treatment of Diabetes / Insulin Resistance: PCT-Worldwide application “Claims all UALA for the treatment of insulin resistance.” Granted in US June 2013- Worldwide pending US Exp-Sept 2028

3- 3- Treatment of Diabetic Nephropathy:Treatment of Diabetic Nephropathy: PCT-Worldwide application “Claims all UALA for the treatment of Diabetic Nephropathy” Exp-July 2028

4-4- Improved Dosing Formulation of Xanthine Oxidase Inhibitor:Improved Dosing Formulation of Xanthine Oxidase Inhibitor:“Claims All XOI in dosing formulation for treatment of Hypertension, Insulin Resistance, Prevention of Diabetes, Prevention of Diabetic Nephropathy” PCT-Worldwide application, Exp-Mar 2033

5- 5- Treatment of Metabolic SyndromeTreatment of Metabolic Syndrome::US Patent Application Number 11/995,943 entitled: “Compositions and Methods for Treatment US Patent Application Number 11/995,943 entitled: “Compositions and Methods for Treatment and Treatment of Hyperuricemia Related Health Consequences” and Treatment of Hyperuricemia Related Health Consequences” Exp-Jan 2028Exp-Jan 2028

FDA Approvable Indications: FDA Approvable Indications:

11

RAAS = renin-angiotensin-aldosterone system activation

Competitive Analysis: HypertensionCompetitive Analysis: Hypertension

Treats CauseTreats Cause Cost to Cost to PatientPatient

Lowers Lowers BPBP

Renal Renal ConcernConcern

1’ Side 1’ Side EffectEffect

XORLO (UALA)XORLO (UALA) YESYESSUA, RAAS, InsulinSUA, RAAS, Insulin

LowLow YES ++YES ++ NoneNone Rash ~1%Rash ~1%

Thiazides (#1) Thiazides (#1) NONO LowLow YES YES KnownKnown Worsens Met SynWorsens Met Syn

ACEI (#2)ACEI (#2) RAAS onlyRAAS only ModestModest YES YES ConcernConcernWorsens Met SynWorsens Met SynDry Cough ~20%Dry Cough ~20%

12

Contraindicated for hyperuricemia

ConclusionConclusion• Niche 1: Only 50% of patient have adequately controlled BP, thus need for new MoA Niche 1: Only 50% of patient have adequately controlled BP, thus need for new MoA

(CDC.gov)(CDC.gov)

• Niche 2: Physicians first choice- Thiazides are contraindicated further support for new MoA. Niche 2: Physicians first choice- Thiazides are contraindicated further support for new MoA. (~33% of prescriptions for BP)(~33% of prescriptions for BP)

• Niche 3: Recent evidence suggests ACEI may worsen kidney function.Niche 3: Recent evidence suggests ACEI may worsen kidney function.

• KEY:KEY: Treats cause & does not worsen metabolic syndrome! Treats cause & does not worsen metabolic syndrome!

• Overall XORLO will be ideal first choice therapy (lower BP and prevent kidney injury)! Overall XORLO will be ideal first choice therapy (lower BP and prevent kidney injury)!

XORLO Target MarketsXORLO Target Markets

US Market Size (individuals/year): US Market Size (individuals/year):

• Adolescent Hypertension: Adolescent Hypertension: ~2.8 million~2.8 million• New Onset Hypertension:New Onset Hypertension: ~63 million ~63 million

• Treatment of:Treatment of:• Diabetic Nephropathy:Diabetic Nephropathy: ~10 million~10 million• Diabetes/ Insulin Resistance: Diabetes/ Insulin Resistance: ~86 million~86 million• Metabolic Syndrome –Fatty Liver Metabolic Syndrome –Fatty Liver ~10 million~10 million

13

Strong Management TeamStrong Management Team

Allen Davidoff, Ph.D., CEO and PresidentAllen Davidoff, Ph.D., CEO and President• Former Co-Founder & CSO of Stem Cell TherapeuticsFormer Co-Founder & CSO of Stem Cell Therapeutics• 12 Years Drug Development Experience- Bench to NDA12 Years Drug Development Experience- Bench to NDA• 8 yrs –C Level management experience-CSO, VP- Product Development8 yrs –C Level management experience-CSO, VP- Product Development• 2 IND’s – 9 Clinical trials – 1 NDA2 IND’s – 9 Clinical trials – 1 NDA

Jennifer Toddhunter, CFOJennifer Toddhunter, CFO• Current CFO of African Queen Mines.• Ms. Todhunter has served as VP Financial Administration, and prior to that served as the Finance Manager of both African

Queen Mines and it predecessor , Pan African Mining Corp., since May 2005. • 14 yrs. experience with public companies, predominantly those in the mining industry.

Irwin Olian, ChairmanIrwin Olian, Chairman• Current Chairman and CEO African Queen Mines Ltd.• Founder and served as CEO and Chairman of Pan African Mining Corp. until its acquisition by Asia Thai Mining Co. Ltd. in June

2008.• Co-founder and principal shareholder of North American Scientific, Inc., a Los Angeles based manufacturer of radioisotope

products for the treatment of prostate cancer. • Senior Vice President, Investments, with Sutro & Co. Inc., an established investment banking and brokerage firm in San

Francisco. • He also served as Vice President of Bear Stearns & Co. Inc.

14

Strong Management Team (Continued) Strong Management Team (Continued)

Grace Jung, Ph.D., Director Manufacturing and Synthetic Chemistry Grace Jung, Ph.D., Director Manufacturing and Synthetic Chemistry • 21 years of experience in drug discovery and development• Former Senior Director of Research (Chemistry) at Cardiome. • Led the chemistry team in the discovery of antiarrhythmic vernakalant. Prior to Cardiome, Grace spent 7

years at Boehringer Ingelheim - medicinal chemist- renin inhibitors as antihypertensive drugs.

Brian Mangal, M.Sc., Director Business Development Brian Mangal, M.Sc., Director Business Development • 12 years of clinical and regulatory development experience.• Formerly Director Biostatistics at Cardiome.• Extensive Clinical , Regulatory and Corporate development experience includes design, analysis and

reporting of over 50 clinical trials, three FDA submissions, one TPD submission, a successful EMEA submission and numerous interactions with regulatory authorities and large pharma partner accounts.

Alan Moore, Ph.D., Founding Board Member, Executive Consultant : Clinical and Regulatory Affairs Alan Moore, Ph.D., Founding Board Member, Executive Consultant : Clinical and Regulatory Affairs • 27 years pharmaceutical development experience with 23 years of senior management experience in

pharmaceutical R&D with P&G• Completed 11 investigational new drug ("IND") applications or supplemental IND's, 15 phase I studies, 12

phase II studies, 7 phase III studies and 2 new drug applications. Most recently CEO of BetaStem Inc.

Bob Rieder, President and CEO- EssaPharmaceuticalsBob Rieder, President and CEO- EssaPharmaceuticals• Current Chairman and Former Co-Founder & CEO Cardiome Pharma• Led successful development of antiarrythmic drug Vernakalant through European Registration &

Partnership• 25 yrs –C Level management experience-President, CEO, director

15

Clinical Advisory BoardClinical Advisory Board

Dr. Richard J. Johnson:Dr. Richard J. Johnson: Dr. Johnson is Chief of the Division of Renal Diseases and Hypertension at the University of Dr. Johnson is Chief of the Division of Renal Diseases and Hypertension at the University of Colorado.Colorado. Temple Hoyne Buell and NKF of Colorado Endowed Professor of Medicine Chief, Division Temple Hoyne Buell and NKF of Colorado Endowed Professor of Medicine Chief, Division of Renal Diseases & Hypertension University of Colorado Denver. Dr. Johnson is nationally and of Renal Diseases & Hypertension University of Colorado Denver. Dr. Johnson is nationally and internationally renowned for his work on mechanisms of renal injury and progression, including in internationally renowned for his work on mechanisms of renal injury and progression, including in glomerulonephritis, diabetes, and hypertension. Recent studies have focused on the pathogenesis of glomerulonephritis, diabetes, and hypertension. Recent studies have focused on the pathogenesis of essential hypertension and the role of subtle renal injury. He has also performed extensive research essential hypertension and the role of subtle renal injury. He has also performed extensive research on the role of uric acid and fructose in the epidemic of obesity, metabolic syndrome, diabetes, and on the role of uric acid and fructose in the epidemic of obesity, metabolic syndrome, diabetes, and hypertension. hypertension.

Dr. Daniel FiegDr. Daniel Fieg: : Dr. Fieg is DDr. Fieg is Director of the Pediatric Hypertension Program and Pediatric Renal Transplant Program at irector of the Pediatric Hypertension Program and Pediatric Renal Transplant Program at the University of Alabama, Birmingham. He also serves on the steering/planning committee for the the University of Alabama, Birmingham. He also serves on the steering/planning committee for the hypertension studies being conducted by the Pediatric Trials Network. hypertension studies being conducted by the Pediatric Trials Network.

Dr. William Hiatt:Dr. William Hiatt:Dr. Hiatt has successfully led CPC as President since 1996. He is a past Chair of the United States Dr. Hiatt has successfully led CPC as President since 1996. He is a past Chair of the United States Food and Drug Administration (FDA) Cardiovascular and Renal Advisory Committee (2003-08) and Food and Drug Administration (FDA) Cardiovascular and Renal Advisory Committee (2003-08) and currently serves on the Endocrinologic and Metabolic Drugs Advisory Committee. In addition, Dr. currently serves on the Endocrinologic and Metabolic Drugs Advisory Committee. In addition, Dr. Hiatt is the Novartis Foundation endowed professor for cardiovascular research in the Department Hiatt is the Novartis Foundation endowed professor for cardiovascular research in the Department of Medicine, Division of Cardiology, University of Colorado School of Medicine.of Medicine, Division of Cardiology, University of Colorado School of Medicine.

16

The FutureThe Future

The current funding will be utilized to plan, develop and carry-out a Phase II The current funding will be utilized to plan, develop and carry-out a Phase II program of FDA clinical trials. This could lead to the following: program of FDA clinical trials. This could lead to the following:

•Licensing Deal Licensing Deal ((anticipated as early as 2016-2017anticipated as early as 2016-2017))

•AcquisitionAcquisition

Recent Comparative Post Phase II deals:Recent Comparative Post Phase II deals:2012- $1.26 Billion , AstraZeneca acquired Ardea2012- $1.26 Billion , AstraZeneca acquired Ardea

Lead Product: Uric acid lowering agent for GoutLead Product: Uric acid lowering agent for Gout

2009- $900 M , Novartis acquired Speedel 2009- $900 M , Novartis acquired Speedel Lead Product: Hypertension agent.Lead Product: Hypertension agent.

Average deal value - $1.1 BAverage deal value - $1.1 B

17

Potential Pharmaceutical Partners Potential Pharmaceutical Partners

• TakedaTakeda Febuxostat Febuxostat

• AstraZenecaAstraZeneca Lesurinad Lesurinad (repurposed (repurposed drugs 50%)drugs 50%)

• GSKGSK Allopurinol Allopurinol

• NovartisNovartis Hypertension Hypertension

• MerckMerck Hypertension Hypertension

18

Brokered Private PlacementBrokered Private Placement

$ 3 million to $ 6 million CAD$ 3 million to $ 6 million CAD

12 Million Units @ 12 Million Units @ $0.50 per Unit $0.50 per Unit ((Each Unit will be comprised of Each Unit will be comprised of one common share and one-half of one share purchase warrant one common share and one-half of one share purchase warrant

entitling the holder to purchase one additional share at an entitling the holder to purchase one additional share at an exercise price $0.75 for two years.)exercise price $0.75 for two years.)

Use of Proceeds: Use of Proceeds: API manufacturingAPI manufacturing

Pre-IND FDA, IND, Phase II protocolPre-IND FDA, IND, Phase II protocolXORLO Phase II Hypertension StudyXORLO Phase II Hypertension Study

19

XORTX Pharma Corp. XORTX Pharma Corp.

Proforma Capitalization (Post Merger and Financing)Proforma Capitalization (Post Merger and Financing)Shares Outstanding: Shares Outstanding: ~ ~ 41,000,00041,000,000

Options and Warrants Outstanding: Options and Warrants Outstanding: ~~ 10,550,00010,550,000

Offering Price: $0.50 CADOffering Price: $0.50 CAD

Market Cap: $ 20.5 M CADMarket Cap: $ 20.5 M CAD

Management and Insiders approximately 20%Management and Insiders approximately 20%

Note: These numbers assume the full $ 6 M financing.Note: These numbers assume the full $ 6 M financing.

20

The XORTX Corporate HighlightsThe XORTX Corporate Highlights

1.1. KEY Thought Leaders:KEY Thought Leaders: Dr. Richard Johnson has defined ‘causative’ role of Serum Uric Dr. Richard Johnson has defined ‘causative’ role of Serum Uric Acid in hypertension, insulin resistance, diabetes, Diabetic Nephropathy. Dr. Will Hiatt Acid in hypertension, insulin resistance, diabetes, Diabetic Nephropathy. Dr. Will Hiatt former FDA head of Cardio-Renal advisory committee and now advises on the XORTX former FDA head of Cardio-Renal advisory committee and now advises on the XORTX Scientific Advisory Board.Scientific Advisory Board.

2.2. XORTX Controls Intellectual Property Portfolio XORTX Controls Intellectual Property Portfolio - claims for five patent families that cover - claims for five patent families that cover use of “all uric acid lowering agents” for of Hypertension, Insulin Resistance, Metabolic use of “all uric acid lowering agents” for of Hypertension, Insulin Resistance, Metabolic Syndrome, Diabetes Prevention. Syndrome, Diabetes Prevention.

3.3. Strong Management TeamStrong Management Team - experience in early drug development to market approval, - experience in early drug development to market approval, tailored to developing Oxypurinol through New Drug Application (NDA).tailored to developing Oxypurinol through New Drug Application (NDA).

4.4. Lower development costs and faster time to market Lower development costs and faster time to market – pursuing 505(b)(2) FDA Pathway, – pursuing 505(b)(2) FDA Pathway, targeting hypertension market launch possible in 2019.targeting hypertension market launch possible in 2019.

5.5. Four Phase II clinical trials validate IP conceptFour Phase II clinical trials validate IP concept: show clinically meaningful and statistically : show clinically meaningful and statistically significant effects of lowering serum uric on Early-Stage Hypertension & Progressive significant effects of lowering serum uric on Early-Stage Hypertension & Progressive Renal Injury.Renal Injury.

6.6. Recent relevant M&A transactionsRecent relevant M&A transactions demonstrates market appetite for this therapeutic demonstrates market appetite for this therapeutic space and validates the return on investment opportunity.space and validates the return on investment opportunity.

21

Contact Information:

Innovation, Discovery and Practical Solutions for the Innovation, Discovery and Practical Solutions for the Management of Hypertension and the Prevention of Management of Hypertension and the Prevention of

Diabetes and Diabetic Nephropathy Diabetes and Diabetic Nephropathy

Dr. Allen Davidoff, XORTX Pharma Corp. www.xortx.comadavidoff@xortx.com 1-403-607-2621

22